Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.97 |
| ▸ | DRD2 | P14416 | 1/20 | 0.97 |
| ▸ | PTGES | O14684 | 9/20 | 0.84 |
| ▸ | ALOX5 | P09917 | 8/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.80 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.62 |
| ▸ | CDK2 | P24941 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | AURKA | O14965 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lonazolac SCHEMBL1478078 | 1.00 | KDM4E (0.97) | KDM4EDRD2PTGESALOX5ALDH1A1 | |
| Lonazolac SCHEMBL25221 | 0.99 | KDM4E (1.00) | KDM4EDRD2PTGESALOX5ALDH1A1 | |
| SCHEMBL11245260 | 0.93 | KDM4E (0.90) | KDM4EDRD2PTGESALOX5ALDH1A1 | |
| SCHEMBL11166545 | 0.93 | KDM4E (0.90) | KDM4EDRD2PTGESALOX5ALDH1A1 | |
| SCHEMBL10877279 | 0.90 | KDM4E (0.83) | KDM4EDRD2PTGESALOX5ALDH1A1 | |
| SCHEMBL10407060 | 0.89 | KDM4E (1.00) | KDM4EDRD2PTGESALOX5ALDH1A1 | |
| SCHEMBL3475488 | 0.88 | KDM4E (0.81) | KDM4EDRD2PTGESALOX5ALDH1A1 | |
| SCHEMBL12608902 | 0.88 | KDM4E (0.81) | KDM4EDRD2PTGESALOX5ALDH1A1 | |
| SCHEMBL11258042 | 0.87 | KDM4E (0.79) | KDM4EDRD2PTGESALOX5ALDH1A1 | |
| Lonazolac SCHEMBL10577835 | 0.87 | PTGES (1.00) | KDM4EDRD2PTGESALOX5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 511 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| WO-2008069546-A1 | ORAL ADMINISTRATIVE PREPARATION FOR TREATING CARDIOVASCULAR SYSTEM DISEASE | BORYUNG PHARMACEUTICAL CO., LTD (KR) | 2008-06-12 | — | — | WO | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20250345206-A1 | APPARATUS AND METHODS FOR OCULAR INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-12350261-B2 | Methods and devices for the treatment of ocular diseases in human subjects | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250186253-A1 | DEVICES AND METHODS FOR ADJUSTING THE INSERTION DEPTH OF A NEEDLE FOR MEDICAMENT DELIVERY | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| EP-4566672-A2 | METHODS FOR THE TREATMENT OF OCULAR DISEASE IN HUMAN SUBJECTS | Clearside Biomedical Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-3554435-B1 | SYSTEMS FOR DELIVERING DRUGS TO RETINAL TISSUE | CLEARSIDE BIOMEDICAL INC (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250152413-A1 | SYSTEMS, DEVICES, AND METHODS FOR NEEDLE-LESS OCULAR INJECTIONS | CLEARSIDE BIOMEDICAL INC (US) | 2025-05-15 | — | — | US | disclosed |
| EP-3721872-B1 | METHODS FOR THE TREATMENT OF OCULAR DISEASE IN HUMAN SUBJECTS | CLEARSIDE BIOMEDICAL INC (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12201558-B2 | Apparatus and methods for ocular injection | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| EP-0156233-A2 | Use of leukotriene antagonists for producing cytoprotective pharmaceutical compositions and process for producing cytoprotective pharmaceutical compositions | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | disclosed |
| EP-0155623-A2 | Use of lipoxygenase inhibitors for the preparations of cytoprotective pharmaceutical compostions and process for the preparation of a cytoprotective pharmaceutical composition | MERCK & CO. INC. (US) | 1985-09-25 | — | — | EP | disclosed |
| EP-0146243-A1 | Lipoxygenase inhibitors | MERCK FROSST CANADA INC. (CA) | 1985-06-26 | — | — | EP | disclosed |
| EP-0140709-A2 | 5-Lipoxygenase inhibitors | MERCK FROSST CANADA INC. (CA) | 1985-05-08 | — | — | EP | disclosed |
| EP-0140684-A2 | Leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1985-05-08 | — | — | EP | disclosed |
| EP-0138481-A2 | Leukotriene biosynthesis inhibitors | MERCK FROSST CANADA INC. (CA) | 1985-04-24 | — | — | EP | disclosed |
| EP-0136893-A2 | Benzo[a]phenothiazines and hydro-derivatives and pharmaceutical compositions containing them | MERCK FROSST CANADA INC. (CA) | 1985-04-10 | — | — | EP | disclosed |
| EP-0123543-A1 | Leukotriene antagonists, their production and use and compositions containing them | MERCK FROSST CANADA INC. (CA) | 1984-10-31 | — | — | EP | disclosed |
| EP-0123541-A1 | Leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1984-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | KDM4E 4530/4885DRD2 1623/4885PTGES 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.